Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -923.59% | 200.59% | -152.34% | 114.68% | -83.33% |
| Total Depreciation and Amortization | 7.35% | 8.42% | 13.62% | 11.54% | 2.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,927.85% | -183.76% | 169.54% | -110.98% | 96.10% |
| Change in Net Operating Assets | -486.47% | 217.64% | -146.40% | 111.35% | -19.26% |
| Cash from Operations | -16.78% | 32.77% | -26.10% | 19.36% | 86.10% |
| Capital Expenditure | 12.79% | -6.76% | 21.14% | -8.04% | 14.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -269.71% | -6.45% | 38.71% | 1,200.00% | 1,386.21% |
| Cash from Investing | -3,313.79% | -12.13% | 22.80% | -273.46% | 106.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -- | 100.00% | -100.00% | 50.00% |
| Issuance of Common Stock | -20.93% | 0.00% | -33.33% | -10.64% | -21.82% |
| Repurchase of Common Stock | 53.09% | -300.00% | 44.65% | -38.64% | -2,068.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.96% | 112.60% | 45.31% | -41.10% | -- |
| Foreign Exchange rate Adjustments | 427.78% | -100.00% | 114.86% | -526.32% | -166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.67% | 72.68% | 488.89% | -480.08% | 13.27% |